He has established multiple relationship and collaborations with local academic institutions developing significantly improved agro-growth methods, plant genetics techniques, chemical stabilization protocols, and many other developments all aimed at maximizing medicinal value in botanical produce.

Government licensed grower of medical Cannabis since 2008, Hagai has established an advanced research facility and labs for the cultivation of unique Cannabis genetic strands and production of Botanical Cannabinoids for the Pharma, Medical Cosmetics and Food Supplements industries.

Dr. Gedo possesses extensive expertise in international marketing, branding, entrepreneurship, and business strategy. As a Senior Manager, Dr. Gedo has contributed to a wide range of branding, strategic planning, and market penetration activities of major companies in a variety of industries. As a consultant, Dr. Gedo provided services to companies in the medical, food, nutritional supplements, and pharma industries. In parallel to his business and consulting practice, Dr. Tamir has served as the head of the marketing department and other faculty positions of several colleges in Israel and was a guest lecturer in the Department of Business Administration of Shanghai University.

Over the years, he has taught undergraduate and graduate level courses in global marketing, business strategy, innovation, and entrepreneurship. Dr. Gedo received his Ph.D. in Behavioral Economics from Manchester Business School (UK) and an MBA from Ben Gurion University (Israel). He completed a B.Sc. in Molecular Biology at Bar Ilan University (Israel).

He has played an instrumental role in successful IPOs, M&A, spin-offs, and fund raising into private and public companies, with extensive experience in capital markets (Nasdaq, TASE, AIM) and investor relations. Mr. Goldman served from 2012 until recently as CFO of Syneron Medical Ltd, a global leader in the aesthetic medical devices, was traded on Nasdaq until acquired by APAX. Previously, served as CFO of: Retalix, Ltd., a leading global provider of software and services to high volume, high complexity retailers that was dual-listed on Nasdaq and the TASE until it was acquired by NCR Corporation, AxisMobile, taking it public in London on the AIM stock exchange, VocalTec Communications Ltd., a pioneer in VoIP that was listed on Nasdaq and Motorola Semiconductor Israel (acquired by Freescale Semiconductor Inc.). Mr. Goldman began his career at PWC, holds a bachelor’s degree in Accounting and Economics from the University of Tel-Aviv and an Executive M.B.A. from Bradford University with distinction. He is a certified public accountant in Israel and member of the Steering Committee of the Israeli CFO Forum.

Where he held several positions of responsibility, including Vice-President, Operations Network strategic planning and Manager of the Kfar Saba Oral Solid Dosages plant, a 900 employee, $100M expense and over $1 Billion revenue pharmaceutical manufacturing plant. Before that Sagi has served as VP R&D and Manufacturing for Optonol, a company specializing in Ophthalmic implants.

Sagi holds an MBA in Business Management as well as a B.Sc in Mechanical engineering, both from the  Ben Gurion University in Beer Sheba.

In his prior role, he was the Vice President, Clinical Therapeutic Area Head, Cardiovascular, Metabolic, Renal Disease (CVRM) at MedImmune, the biotech arm of AstraZeneca. In that role, he was accountable for all early clinical development plans and clinical trials within CVRM; and chaired various committees

Additionally, Prof. Raz is President of D-Cure, a non-profit organization that promotes and funds scientific research in Israel for finding a cure and better treatments for diabetes. He previously served as president of the Israel Diabetes Association. Prof Raz has performed numerous animal and clinical studies in Diabetes and published them in peer reviewed journals. Prof Raz studied at the Hadassah Hebrew University Medical School in Jerusalem.

His research is focused on polymeric nano and microparticulate and lipid-based drug delivery systems aimed at improving ocular bioavailability, dermal penetration and drug targeting. Prof. Benita formed and supervises a large research lab, has published numerous research articles and book chapters and has multiple patents and patent applications. Prof. Benita has served as a member of the Board of Pharmaceutical Sciences of the International Pharmacy Federation and Governor of the Controlled Release Society.

His research focuses on anti-oxidants and he studies specifically cannabinoids as antioxidants in biological systems; modulation of the skin defense mechanism against stress by cannabinoids, topical nano-delivery of cannabinoids (gold nano particles and microemulsion). He has authored numerous research articles and reviews proceedings, abstracts and book chapters.

Dr Aran initiated studies exploring the effects of medical cannabis on epilepsy and ASD and is the lead researcher of the world’s first clinical study on the efficacy & safety of cannabis for ASD. Dr Aran serves as a consultant to the Ministry of Health for medical cannabis indications and use in children and spends much time educating physicians and lay audiences on the subject. He trained at the Hebrew University-Hadassah Medical School, Jerusalem, Israel and the Biochemistry Department of Psychiatry, Stanford University.

He is a professor in the Department of Child and Adolescent Psychiatry, Hassenfeld Children’s Hospital at NYU Langone, and Professor of Radiology and Neuroscience at the NYU Langone Health School of Medicine.

She has vast clinical and basic research experience in Glioblastoma and has published multiple articles in peer-reviewed journals. She has trained at the Sheba Medical Center, completed a Postdoctoral Fellowship. at the Lawrence National Laboratory, University of California, Berkeley, and completed a Neurosurgical Fellowship at Johns Hopkins University School of Medicine, Baltimore.

Mr. Amital’s papers mainly focus on autoimmunity research primarily in new avenues for the roles of vitamin D, use of biological therapy, pain and comorbidities of fibromyalgia and epidemiological studies based on Health Maintenance Organization databases.

and has played a key part in defining the regulations and indications of medical cannabis use in Israel. He has extensive clinical experience with Cannabis and has conducted and published numerous studies in the Cannabis area. He trained in Anesthesia and Pain Management at Beth Israel Hospital, Harvard Medical School.

Dr. Brill is also an executive member of the Israeli Pain Association and serves as the General Secretary of the executive board of the pain division of the Israeli Anesthesia Association. He also served as Co-Chair of the European Pain Federation task force on Cannabinoids and as Honorary Secretary, EFIC (European Federation of IASP Chapters). He runs one of the leading pain management clinics in Israel and has extensive clinical and scientific experience in the cannabis field.

He previously served as Chairman of the Orthopedics Department at Hasharon Hospital and as Head of the Orthopedic Oncology Unit at Assaf Harofe Hospital. Dr. Robinson is a senior lecturer in the Department of Orthopedic Surgery at Tel Aviv University’s Sackler School of Medicine. His research concentrates on the repair of cartilage injuries using autologous cells, either cultured chondrocytes or mesenchymal cells. He has conducted numerous animal and human trials and published many articles in peer-reviewed journals.

He serves as a member of the National Committee for the Prevention and Treatment of Malignant Diseases, of the Israel Ministry of Health, and the Israeli National Committee for Clinical Trials. He has received numerous awards for his scientific work covering both basic research and clinical aspects of solid tumors. Professor Wolf completed his Postdoctoral Fellowship at the Division of Hematology Oncology, Cedar-Sinai Medical Center, UCLA School of Medicine.

He is a principal investigator with research grants from the Israeli Academy of Science, Israel Association of Cancer Research and the Bi-national Science Foundation and a reviewer for multiple journals and funding agencies. He Trained at the Hadassah Medical Center in Internal Medicine and Gastroenterology and Hepatology and did his Research Fellowship at Massachusetts General in Boston.

Prof. Soriano is the author of numerous articles on gynecological and endometriosis surgery. He was previously President of the Israel Society of Gynaecological Endoscopy. Prof. Soriano is a Professor of Obstetrics and Gynaecology at the Sackler School of Medicine at Tel Aviv University. He is a member of the European Society of Human Reproduction and Embryology and takes part in defining the treatment guidelines on Endometriosis.

He was also previously the R&D Manager at Nova Pharm. Co. His research focuses on biodegradable polymers, pharmaceutical formulations, drug delivery systems and medicinal chemistry, and has resulted in several products, including: Gliadel, Superfloc, Deximmune, Bioprotect, Inspace, Cunker Cover, OraMiost and MAZE. Prof. Domb earned his Bachelor’s degrees in Chemistry, Pharmaceutics and Law Studies, as well as a PhD degree in Chemistry from The Hebrew University of Jerusalem. He did his postdoctoral training at MIT and Harvard University.

He has over 15 years of experience in the field of pharmacokinetics and pharmacodynamics, specializing in the biological aspects of drug delivery systems. He has conducted many PK and PD studies have authored multiple book chapters and hold several patents. Specifically, he published a study on “Affecting Intestinal First Pass Metabolism Processes of Orally Administered Drugs by Pharmaceutical Methodology: The Cannabinoids Paradigm”.

He founded Bioforum Applied Knowledge Center, an international faculty of life-sciences, and Bioforum the Data Masters, a global data-focused CRO, and IMP, clinical supply chain manager. Mr. Malka is a member of several life sciences and clinical trial associations and is an active advocate in helping break down barriers to help further advance these medical industries in Israel.